查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1178161

缺血性中风的全球市场:市场规模 - 各诊断，各药物类别，各手术，各终端用户，各地区展望，竞争策略，各市场区隔预测(～2032年)

Ischemic Stroke Market Size- By Diagnosis, By Drug Class, By Surgery, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 248 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球缺血性中风的市场规模，预计至2032年达到135亿4,000万美元，以4.24％的年复合成长率成长。

由于健康意识的高涨，糖尿病患者增加，香烟使用数量增加，人口的高龄化等要素，牵引市场。缺血性中风的检测和治疗方法相关新开发技术的发展，对市场成长也有所贡献。

本报告提供全球缺血性中风市场相关调查，市场动态，市场变数与展望，各诊断、药物类别、手术、终端用户、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球缺血性中风市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球缺血性中风市场:各诊断(2019年～2032年(100万美元))

  • 颈动脉超音波
  • 大脑超音波
  • 复合血管造影术
  • 心臟超音波图
  • 心电图
  • 磁振造影
  • 其他

第7章 全球缺血性中风市场:各药物类别(2019年～2032年(100万美元))

  • 组织纤维蛋白溶酶原活化剂
  • 抗凝固剂
  • 抗血小板剂
  • 降压剂
  • 其他

第8章 全球缺血性中风市场:各手术(2019年～2032年(100万美元))

  • 血管成形术
  • 颈动脉内薄膜剥离术
  • 血管内机械性血栓消除术

第9章 全球缺血性中风市场:各终端用户(2019年～2032年(100万美元))

  • 医院、诊所
  • 医疗机关
  • 研究机关
  • 其他

第10章 全球缺血性中风市场:各地区(2019年～2032年(100万美元))

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第11章 企业简介

  • Abott Laboratories
    • 企业概要
    • 财务展望
    • 产品概要
    • 最近的开发
  • Bayer AG
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien plc
  • GE Healthcare
  • Genentech, Inc.
  • Jhonson & Jhonson
  • Koninklijke Philips N.V.
  • Medtronic plc
  • Merck & Co. Inc.
  • Philips Healthcare
  • Sanofi
  • Stryker Corporation
简介目录
Product Code: HLCA2231

Global Ischemic Stroke Market Overview:

According to SPER Market Research, the Global Ischemic Stroke Market is estimated to reach USD 13.54 billion by 2032 with a CAGR of 4.24%.

Strokes can also happen when the blood supply to the brain is cut off. Strokes frequently happen when a blood vessel in the brain rupture, allowing haemorrhage to escape. This fracture, or any other sort of obstruction, prevented the blood and oxygen from reaching the brain tissues. Transient ischemic attack (TIA), haemorrhagic stroke, or ischemic stroke are the three main types of strokes that affect everyone in the globe. This procedure uses popular diagnostic tools like echocardiograms, MRIs, CT scans, cerebral angiograms, and blood tests. Treatments for this condition include aspirin, other antiplatelet medications, and anticoagulants.The market for ischemic stroke is being driven by factors such increased health awareness, rising diabetes rates, a rise in tobacco use, and an ageing population. However, the development of new developing technologies for ischemic stroke detection and treatment methods also contributes to the market growth. The maximum amount of blood typically stops abruptly reaching certain parts of the brain, which is how an ischemic stroke usually happens. The region and mechanism of ischemic strokes can be separated. Depending on how they grow within the bodily components, all blood clots inside the body are either thrombotic or embolic.There are expected to be significant growth opportunities in the market for acute ischemic stroke diagnosis and treatment as a result of increased public awareness of stroke and the range of market-available treatments, encouraging government initiatives, and the quickening pace of technological advancements in surgical procedures.The market for the diagnosis and treatment of acute ischemic stroke is expected to grow, but this is expected to be constrained by the high cost of care and the unfavourable reimbursement environment. Additionally, there may be challenges due to the numerous issues associated with product development and manufacturing.

Impact of COVID-19 on the Global Ischemic Stroke Market

According to the Ischemic Stroke market analysis, the virus known as the severity of acute respiratory syndrome of coronavirus 2 that is spread within people is the cause of this condition. Additionally, there has been a slight decline in hospital sectors as a result of the COVID-19 pandemic. It was as a result of individuals becoming afraid of the infection during the lockdown and distance-keeping phase. For health emergencies, a number of nations imposed a rigorous lockdown on their territory. The international trade and business sectors have been suspended for a while. The need for cutting-edge medical equipment has already increased during the lockdown.The COVID-19 has had a direct impact on the global hospital and healthcare industries. Overall, the disease had a very seriously detrimental effect on the market value for ischemic strokes. Investors have suffered a significant loss as a result of the decline in production and manufacturing work. Furthermore, because of several hospital-based therapies for ischemic stroke patients, the major companies in this business are obligated to cut their investment in raw materials and resources. It is also one of the most crucial things to go through at this difficult time. Since every worldwide industry has been severely impacted by this epidemic, most manufacturers aim to satisfy the needs of many industries.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Diagnosis, By Drug Class, By Surgery, By End User

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Abott Laboratories, Bayer AG, Boehringer Ingelheim, Boston Scientific Corporation, Cordis Corporation, Covidien plc, GE Healthcare, Genentech, Inc., Jhonson & Jhonson, Koninklijke Philips N.V., Medtronic plc, Merck & Co., Inc., Philips Healthcare, Sanofi, Stryker Corporation

Global Ischemic Stroke Market Segmentation:

By Diagnosis: Based on the Diagnosis, Global Ischemic Stroke Market is segmented as; Carotid Ultrasound, Cerebral Angiography, Computed Tomography, Echocardiography, Electrocardiography, Magnetic Resonance Imaging, Others.

By Drug Class: Based on the Drug Class, Global Ischemic Stroke Market is segmented as; Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, Antihypertensive, Others.

By Surgery: Based on the Surgery, Global Ischemic Stroke Market is segmented as; Angioplasty, Carotid Endarterectomy, Endovascular Mechanical Thrombectomy.

By End User: Based on the End User, Global Ischemic StrokeMarket is segmented as; Hospitals & Clinic, Medical Institutes, Research Organization, Others.

By Region: Due to rapid technological improvement in the acute ischemic stroke treatment process and supportive government policies, the North American area dominates the acute ischemic stroke diagnosis and treatment market. Because of the rise in ischemic stroke Asia-Pacific is anticipated to develop much faster than the global average.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Ischemic Stroke Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Ischemic Stroke Market, By Diagnosis, 2019-2032 (USD Million)

  • 6.1. Carotid Ultrasound
  • 6.2. Cerebral Ultrasound
  • 6.3. Compound Angiography
  • 6.4. Echocardiography
  • 6.5. Electrocardiography
  • 6.6. Magnetic Resonance Imaging
  • 6.7. Others

7. Global Ischemic Stroke Market, By Drug Class, 2019-2032 (USD Million)

  • 7.1. Tissue Plasminogen Activator
  • 7.2. Anticoagulant
  • 7.3. Antiplatelet
  • 7.4. Antihypertensive
  • 7.5. Others

8. Global Ischemic Stroke Market, By Surgery, 2019-2032 (USD Million)

  • 8.1. Angioplasty
  • 8.2. Carotid Endarterectomy
  • 8.3. Endovascular Mechanical Thrombectomy

9. Global Ischemic Stroke Market, By End User, 2019-2032 (USD Million)

  • 9.1. Hospitals & Clinic
  • 9.2. Medical Institutes
  • 9.3. Research Organization
  • 9.4. Others

10. Global Ischemic Stroke Market, By Region, 2019-2032 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. Abott Laboratories
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Bayer AG
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Boehringer Ingelheim
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Boston Scientific Corporation
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Cordis Corporation
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Covidien plc
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. GE Healthcare
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Genentech, Inc.
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Jhonson&Jhonson
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Koninklijke Philips N.V.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Medtronic plc
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. Merck & Co. Inc.
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Philips Healthcare
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Sanofi
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Stryker Corporation
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments